NeuBase Therapeutics (STU:O7P) Operating Cash Flow per Share : €-7.84 (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Operating Cash Flow per Share?

NeuBase Therapeutics's operating cash flow per share for the three months ended in Sep. 2023 was €-0.68. NeuBase Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was €-7.84.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 41.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 49.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 14.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for NeuBase Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

STU:O7P' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -187.6 Med: -14.6 Max: 67.8
Current: 41

During the past 13 years, NeuBase Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.80% per year. The lowest was -187.60% per year. And the median was -14.60% per year.

STU:O7P's 3-Year OCF Growth Rate is ranked better than
86.55% of 1234 companies
in the Biotechnology industry
Industry Median: 3.5 vs STU:O7P: 41.00

NeuBase Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for NeuBase Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Operating Cash Flow per Share Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Operating Cash Flow per Share

Get a 7-Day Free Trial

-144.51

-57.70

-6.24

-9.27

-11.75

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-4.15	-3.25	-1.92	-1.99	-0.68

Competitive Comparison of NeuBase Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, NeuBase Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuBase Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Price-to-Operating-Cash-Flow falls into.

NeuBase Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

NeuBase Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Sep. 2021 is calculated as

Operating Cash Flow per Share (A: Sep. 2021 )	=	Cash Flow from Operations (A: Sep. 2021 )	/	Shares Outstanding (Diluted Average) (A: Sep. 2021 )
	=	-16.043	/	1.365
	=	-11.75

NeuBase Therapeutics's Operating Cash Flow per Share for the quarter that ended in Sep. 2021 is calculated as

Operating Cash Flow per Share (Q: Sep. 2023 )	=	Cash Flow from Operations (Q: Sep. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
	=	-1.877	/	2.758
	=	-0.68

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.84

NeuBase Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines